← boothcheck

LFST vs WGS stock comparison

LifeStance Health Group, Inc. vs GeneDx Holdings Corp., two Medical Services stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.

The margin lines separate a business finding its footing from one still buying it: LifeStance earns a positive 5.5% operating margin on outpatient mental-health visits, GeneDx a negative 56.2% on genomic diagnostics, spending through a 66.7% gross margin toward scale. LifeStance converts 3.5% of its price into free cash; GeneDx burns modestly against a 3.1 current ratio. Neither has earnings to price. The market values them within a factor of two, $4B against $2B, which prices GeneDx's sequencing growth story at a substantial premium per current dollar of anything. Behavioral health compounding quietly against genomics compounding loudly; the quiet one is closer to paying for itself.

Comparison updated 2026-07-10.

LFST vs WGS: the numbers

MetricLFSTWGS
Price$10.26$69.86
Market cap$4.1B$2.0B
SectorMedical ServicesMedical Services
StageGrowthGrowth
P/B2.748.06
P/S2.714.63
EV/EBITDA42.0
Revenue growth+16.4%+35.3%
Gross margin66.7%
Operating margin5.5%-56.2%
Net margin1.6%-17.6%
Return on equity1.6%-30.6%
Return on assets1.1%-15.4%
Return on invested capital1.8%-14.7%
FCF yield3.5%-1.4%
Debt / equity0.200.39
Current ratio1.483.09
Altman Z (solvency)3.921.84
Piotroski F (quality)6 / 91 / 9
Full LFST report → Full WGS report →
Get boothcheck's read on LFST and WGS, and what their prices are betting on, in your inbox. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

Compare any two stocks

vs

The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.